Dr Reddy's Recalls Epilepsy Drug Levetiracetam In US Over Mislabelling Concerns
Dr Reddy's Laboratories Ltd. is recalling one batch of epilepsy drug Levetiracetam in 0.75% sodium chloride injection in the US over mislabelling concerns.
The product's Lot No: A1540076 of Levetiracetam in 0.75% sodium chloride injection, 1,000 mg/100 mL is being recalled because the infusion bag is incorrectly labelled as Levetiracetam in 0.82% sodium chloride injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, according to an exchange filing.
The affected batch was distributed nationwide in the US between Nov. 4 and Nov. 6 to wholesalers. "Because the infusion bag is labelled as 500 mg/100 mL but actually contains 1,000 mg/100 mL dose, the patient could receive double the dose of intravenous levetiracetam than intended, which could lead to adverse events," it said.
The pharmaceutical company issued a risk statement that the patients who are administered the mislabelled product will likely experience serious side effects, including hypersensitivity reactions, liver injury, hematological toxicity, somnolence, fatigue, dizziness, coordination difficulties, agitation, aggression, depressed level of consciousness, respiratory depression, and coma.
Patients receiving high doses of levetiracetam by rapid intravenous infusion for the treatment of status epilepticus would be most at risk for severe adverse events. Dr Reddy's has not received any reports of adverse events related to this recall, the filing said.
Levetiracetam in 0.75% sodium chloride injection 1,000 mg/100 mL, 10 mg/mL, and Levetiracetam in 0.82% sodium chloride injection 500 mg/100 mL, 5 mg/mL are indicated as adjunctive therapy for adults aged 16 years and older when oral administration is temporarily not feasible.
They are used in the treatment of the following seizure types — partial-onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy and primary generalised tonic-clonic seizures.
Dr. Reddy's profit rose 2% in the third quarter of the current financial year, but missed analysts' estimates. The pharmaceutical company posted a bottom line of Rs 1,413.7 crore in the quarter ended December.
Shares of Dr Reddy's closed 0.11% lower at Rs 1,106.35 apiece on the National Stock Exchange, compared to a 0.33% decline in the benchmark NSE Nifty. The stock has fallen 12.41% in the last 12 months.
Fifteen out of 40 analysts tracking the company have a 'buy' rating on the stock, 11 recommend 'hold' and 14 suggest 'sell', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 22%.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.